Compare PAX & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAX | GLPG |
|---|---|---|
| Founded | 1988 | 1999 |
| Country | Cayman Islands | Belgium |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | 2021 | 2005 |
| Metric | PAX | GLPG |
|---|---|---|
| Price | $17.14 | $34.45 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | ★ 457.2K | 122.6K |
| Earning Date | 02-10-2026 | 02-11-2026 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | ★ 58.69 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $405,792,000.00 | $336,643,201.00 |
| Revenue This Year | N/A | $1.76 |
| Revenue Next Year | $22.55 | $0.49 |
| P/E Ratio | $26.04 | ★ N/A |
| Revenue Growth | ★ 23.45 | 10.31 |
| 52 Week Low | $9.43 | $22.36 |
| 52 Week High | $17.80 | $37.78 |
| Indicator | PAX | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 60.27 | 68.91 |
| Support Level | $16.86 | $32.13 |
| Resistance Level | $17.58 | $34.48 |
| Average True Range (ATR) | 0.44 | 0.81 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 65.96 | 92.58 |
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.